JP2019507791A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507791A5 JP2019507791A5 JP2018547929A JP2018547929A JP2019507791A5 JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5 JP 2018547929 A JP2018547929 A JP 2018547929A JP 2018547929 A JP2018547929 A JP 2018547929A JP 2019507791 A5 JP2019507791 A5 JP 2019507791A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- dihydroxybutan
- sulfonamide
- thio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078242A JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307348P | 2016-03-11 | 2016-03-11 | |
| US62/307,348 | 2016-03-11 | ||
| PCT/US2017/021570 WO2017156270A1 (en) | 2016-03-11 | 2017-03-09 | Cxcr-2 inhibitors for treating crystal arthropathy disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Division JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507791A JP2019507791A (ja) | 2019-03-22 |
| JP2019507791A5 true JP2019507791A5 (https=) | 2020-04-30 |
| JP6883917B2 JP6883917B2 (ja) | 2021-06-09 |
Family
ID=59789863
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018547929A Expired - Fee Related JP6883917B2 (ja) | 2016-03-11 | 2017-03-09 | 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤 |
| JP2021078242A Active JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078242A Active JP7126014B2 (ja) | 2016-03-11 | 2021-05-05 | 結晶性関節障害を処置するためのｃｘｃｒ－２阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10772886B2 (https=) |
| EP (1) | EP3426253A4 (https=) |
| JP (2) | JP6883917B2 (https=) |
| CN (2) | CN109152780B (https=) |
| AU (1) | AU2017231832B2 (https=) |
| BR (1) | BR112018068393A2 (https=) |
| CA (1) | CA3017345A1 (https=) |
| CO (1) | CO2018010880A2 (https=) |
| MX (1) | MX386771B (https=) |
| WO (1) | WO2017156270A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109152780B (zh) | 2016-03-11 | 2021-10-01 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| BR112020004697A2 (pt) * | 2017-09-12 | 2020-10-27 | Ardea Biosciences, Inc. | inibidores de cxcr-2 para tratamento de distúrbios |
| EP3738956B1 (en) * | 2018-01-11 | 2023-03-01 | Shenzhen Optimum Biological Technology Co., Ltd | Cxcr2 antagonist |
| CN114286819B (zh) | 2019-07-11 | 2024-03-05 | 深圳嘉科生物科技有限公司 | 一种cxcr2拮抗剂的晶型及其应用 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| TW202210068A (zh) * | 2020-06-05 | 2022-03-16 | 美商雅力思提雅治療公司 | 用於治療家族性地中海型發熱病的cxcr-2抑制劑 |
| WO2022162021A1 (en) * | 2021-01-27 | 2022-08-04 | Astrazeneca Ab | Verinurad compositions and methods of use |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0217431D0 (en) | 2002-07-27 | 2002-09-04 | Astrazeneca Ab | Novel compounds |
| AU2005210504B2 (en) | 2004-01-30 | 2009-01-08 | Merck Sharp & Dohme Corp. | Crystalline polymorphs of a CXC-chemokine receptor ligand |
| KR101280095B1 (ko) | 2004-08-28 | 2013-09-09 | 아스트라제네카 아베 | 케모킨 수용체 조절제로서의 피리미딘 술폰아미드 유도체 |
| AU2008206231A1 (en) * | 2007-01-19 | 2008-07-24 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents |
| EP2203432A4 (en) | 2007-09-21 | 2011-04-27 | Glaxosmithkline Llc | PROCESSING METHOD |
| US20090093548A1 (en) | 2007-10-05 | 2009-04-09 | Mutual Pharmaceutical Company, Inc | Colchine compositions and methods |
| US20110009482A1 (en) | 2007-12-04 | 2011-01-13 | Schering Corporation | Methods of treating copd |
| CN102088993A (zh) | 2008-03-20 | 2011-06-08 | 卡罗勒斯治疗公司 | 炎症的治疗方法 |
| CA2730477A1 (en) | 2008-07-16 | 2010-01-21 | Astrazeneca Ab | Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases |
| JP2012505160A (ja) | 2008-10-06 | 2012-03-01 | カロラス セラピューティクス， インク． | 炎症を処置する方法 |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| WO2010056399A1 (en) | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| US20110256130A1 (en) | 2008-12-01 | 2011-10-20 | Joshua Robert Schultz | Methods of treating inflammatory disorders |
| WO2010071865A1 (en) * | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Pharmaceutical compositions and methods for treating hyperuricemia and related disorders |
| ES2559029T3 (es) | 2009-04-24 | 2016-02-10 | Tissue Tech, Inc. | Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas |
| AU2010298249A1 (en) | 2009-09-23 | 2012-04-19 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| WO2011116245A2 (en) | 2010-03-19 | 2011-09-22 | Carolus Therapeutics, Inc. | Methods of treating inflammation |
| CN103097377A (zh) | 2010-07-13 | 2013-05-08 | 阿斯利康(瑞典)有限公司 | N-[2-[[(2,3-二氟苯基)甲基]硫基]-6-{[(1r,2s)-2,3-二羟基-1-甲基丙基]氧基}-4-嘧啶基]-1-氮杂环丁烷磺酰胺的新晶形 |
| CA2811990C (en) * | 2010-08-23 | 2023-03-21 | Dean Y. Maeda | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| ES2861927T3 (es) * | 2011-07-12 | 2021-10-06 | Astrazeneca Ab | N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina |
| ES2846789T3 (es) | 2012-07-11 | 2021-07-29 | Tissuetech Inc | Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos |
| US20170320954A1 (en) | 2014-11-17 | 2017-11-09 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| US20180221312A1 (en) | 2016-03-11 | 2018-08-09 | Ardea Biosciences, Inc. | Cxcr-2 inhibitors for treating disorders |
| CN109152780B (zh) | 2016-03-11 | 2021-10-01 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| BR112020004697A2 (pt) | 2017-09-12 | 2020-10-27 | Ardea Biosciences, Inc. | inibidores de cxcr-2 para tratamento de distúrbios |
-
2017
- 2017-03-09 CN CN201780029205.4A patent/CN109152780B/zh active Active
- 2017-03-09 US US15/516,465 patent/US10772886B2/en not_active Expired - Fee Related
- 2017-03-09 CN CN202111152242.9A patent/CN113893252A/zh active Pending
- 2017-03-09 JP JP2018547929A patent/JP6883917B2/ja not_active Expired - Fee Related
- 2017-03-09 EP EP17764095.0A patent/EP3426253A4/en not_active Withdrawn
- 2017-03-09 WO PCT/US2017/021570 patent/WO2017156270A1/en not_active Ceased
- 2017-03-09 AU AU2017231832A patent/AU2017231832B2/en not_active Ceased
- 2017-03-09 BR BR112018068393A patent/BR112018068393A2/pt not_active Application Discontinuation
- 2017-03-09 CA CA3017345A patent/CA3017345A1/en active Pending
- 2017-03-09 MX MX2018010946A patent/MX386771B/es unknown
-
2018
- 2018-10-10 CO CONC2018/0010880A patent/CO2018010880A2/es unknown
-
2021
- 2021-05-05 JP JP2021078242A patent/JP7126014B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019507791A5 (https=) | ||
| JP6434416B2 (ja) | ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ−γキナーゼ阻害剤とを含有する薬学的組成物 | |
| BR0309670A (pt) | Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo | |
| US20110046119A1 (en) | Therapeutic treatment | |
| JP2005502643A (ja) | 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 | |
| JP2015535247A5 (https=) | ||
| JP7460772B2 (ja) | コロナウイルス感染症の治療方法 | |
| JP2012184234A5 (https=) | ||
| KR20150046039A (ko) | 심방 확장 또는 재형성을 특징으로 하는 질환을 치료하기 위한 nep 억제제 | |
| JP2013528655A5 (https=) | ||
| BR112015010063A2 (pt) | método para o tratamento ou prevenção de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, utilização de um composto de fórmula (i), um derivado da colquicina conhecido e/ou um sal do mesmo, composição para a prevenção ou tratamento de um evento cardiovascular em um sujeito com doença vascular aterosclerótica, método e regime para reduzir ou prevenir a inflamação induzida por cristal de colesterol no interior das placas ateroscleróticas em um sujeito, regime para o tratamento ou prevenção de um acidente cardiovascular em um indivíduo | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| US20110046190A1 (en) | Combinations comprising a selective cyclooxygenase-2 inhibitor | |
| RU2013145498A (ru) | Способы и композиции для лечения гиперурикемии и метаболических нарушений, связанных с гиперурикемией | |
| JP2014532760A5 (https=) | ||
| JP2014532726A5 (https=) | ||
| JP2021522247A5 (https=) | ||
| JP2013500977A5 (https=) | ||
| RU2009111378A (ru) | Терапевтические композиции, содержащие специфический антагонист рецептора эндотелина и ингибиторов pde5 | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| US20190282542A1 (en) | Capsid assembly modulator dosing regimen | |
| MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
| RU2014115733A (ru) | Новая соль и медицинское применение | |
| KR20230048517A (ko) | 베타 코로나바이러스 감염과 연관된 질환을 치료 또는 예방하기 위한 조성물 및 방법 | |
| JP2015526504A5 (https=) |